Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12

AUTHORS

David Propper, Keith Jones, D. Alan Anthoney, Wasat Mansoor, Daniel Ford, Martin Eatock, Roshan Agarwal, Michiyasu Inatani, Tomohisa Saito, Masaichi Abe, T. R. Jeffry Evans

ABSTRACT

BACKGROUND: TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas. METHODS: Eligible patients had metastatic or locally advanced gastric or Siewert Types II or III GOJ inoperable adenocarcinoma. Patients were chemotherapy naïve unless this had been administered in the perioperative setting. TP300 was administered as a 1-h intravenous infusion every 3 weeks (a cycle) for up to 6 cycles at a starting dose of 8 mg/m2 with intra-patient escalation to 10 mg/m2 from cycle 2 in the absence of dose-limiting toxicity. Tumour responses (RECIST 1.1) were assessed every 6 weeks. Toxicity was recorded by NCI-CTCAE version 3.0. Using a modified two-stage Simon design (Stage I and II), a total of 43 patients were to be included providing there were 3 of 18 patients with objective response in Stage I of the study. RESULTS: In Stage I of the study 20 patients (14 males, 6 females), median age 67 years (range 40 - 82), performance status ECOG 0/1, with GC [14] or GOJ carcinoma [6] were enrolled. Of the 16 evaluable patients, 11 received the planned dose increase to 10 mg/m2 at cycle 2, 2 decreased to 6 mg/m2, and 3 continued on 8 mg/m2. There were no objective responses after 2 cycles of treatment. Twelve patients had stable disease for 1 - 5 months and 4 had progressive disease. Median progression free survival (PFS) was 4.1 months (CI [1.6 - 4.9]), median time to progression (TTP) was 2.9 months (CI [1.4 - 4.2]). Grade 3/4 toxicities (worst grade all cycles) included 7 patients (35 %) with neutropenia, 4 patients (20 %) with anaemia, 2 patients (10 %) with thrombocytopenia, and 3 patients (15 %) with fatigue. This study was terminated at the end of Stage I due to a lack of the required (3/18) responders. CONCLUSIONS: This study of TP300 showed good drug tolerability but it failed to demonstrate sufficient efficacy as measured by radiological response. TRIAL REGISTRATION: EU-CTR 2009-012097-12 2009-09-03. More... »

PAGES

779

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-016-2828-6

DOI

http://dx.doi.org/10.1186/s12885-016-2828-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006376300

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27724887


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophagogastric Junction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterocyclic Compounds, 4 or More Rings", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Queen Mary University of London", 
          "id": "https://www.grid.ac/institutes/grid.4868.2", 
          "name": [
            "Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Lower Ground Floor, Old Anatomy Building, Charterhouse Square, EC1M 6BQ, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Propper", 
        "givenName": "David", 
        "id": "sg:person.01314243636.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314243636.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Chugai Pharmaceuticals Europe Ltd. Turnham Green, W4 1NN, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Keith", 
        "id": "sg:person.0715135174.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715135174.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "St James Institute of Oncology, University of Leeds & Leeds Teaching Hospitals Trust, LS9 7TF, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anthoney", 
        "givenName": "D. Alan", 
        "id": "sg:person.01073332434.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073332434.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Christie Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415720.5", 
          "name": [
            "Department Medical Oncology, Christie Hospital, Wilmslow Road, Withington, M20 4BX, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mansoor", 
        "givenName": "Wasat", 
        "id": "sg:person.0744661266.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744661266.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Birmingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412918.7", 
          "name": [
            "Cancer Research Clinical Trials Team, Old Clinical Investigations Building, City Hospital, Dudley Road, B18 7QH, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ford", 
        "givenName": "Daniel", 
        "id": "sg:person.012750060421.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012750060421.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Belfast City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412914.b", 
          "name": [
            "Northern Ireland Cancer Clinical Trials Unit, Belfast City Hospital, East Podium, C Floor, BT9 7AB, Belfast, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eatock", 
        "givenName": "Martin", 
        "id": "sg:person.01304662546.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304662546.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St Mary's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.426467.5", 
          "name": [
            "West London Cancer Research Network, Coulter Suite, 1st Floor Mint Wing, St Mary\u2019s Hospital, Praed St, W2 1 NY, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agarwal", 
        "givenName": "Roshan", 
        "id": "sg:person.014343021421.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014343021421.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.418587.7", 
          "name": [
            "Chugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, 103-8324, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inatani", 
        "givenName": "Michiyasu", 
        "id": "sg:person.01063747552.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063747552.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.418587.7", 
          "name": [
            "Chugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, 103-8324, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saito", 
        "givenName": "Tomohisa", 
        "id": "sg:person.01010005124.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010005124.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.418587.7", 
          "name": [
            "Chugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, 103-8324, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abe", 
        "givenName": "Masaichi", 
        "id": "sg:person.0630321344.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630321344.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Glasgow", 
          "id": "https://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Beatson West of Scotland Cancer Centre, University of Glasgow, G12 OYN, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "T. R. Jeffry", 
        "id": "sg:person.013162613642.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013162613642.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6601226", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003666440", 
          "https://doi.org/10.1038/sj.bjc.6601226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601226", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003666440", 
          "https://doi.org/10.1038/sj.bjc.6601226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-12-536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005309595", 
          "https://doi.org/10.1186/1471-2407-12-536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.10279", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005653195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jphp.12065", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013198532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdg727", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016118999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.01.140", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016694337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1042-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031264262", 
          "https://doi.org/10.1007/s00280-009-1042-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1042-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031264262", 
          "https://doi.org/10.1007/s00280-009-1042-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1042-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031264262", 
          "https://doi.org/10.1007/s00280-009-1042-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197411)34:5<1576::aid-cncr2820340503>3.0.co;2-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039330995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6690243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039335865", 
          "https://doi.org/10.1038/sj.bjc.6690243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6690243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039335865", 
          "https://doi.org/10.1038/sj.bjc.6690243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044779901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14728222.12.10.1243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046772657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008243606668", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056302730"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1215/15228517-2008-075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064414376"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2005.37.2.79", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2005.37.2.79", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.1.319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074511243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075084732", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075323137", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a059107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082507231"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "BACKGROUND: TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas.\nMETHODS: Eligible patients had metastatic or locally advanced gastric or Siewert Types II or III GOJ inoperable adenocarcinoma. Patients were chemotherapy na\u00efve unless this had been administered in the perioperative setting. TP300 was administered as a 1-h intravenous infusion every 3\u00a0weeks (a cycle) for up to 6\u00a0cycles at a starting dose of 8\u00a0mg/m2 with intra-patient escalation to 10\u00a0mg/m2 from cycle 2 in the absence of dose-limiting toxicity. Tumour responses (RECIST 1.1) were assessed every 6\u00a0weeks. Toxicity was recorded by NCI-CTCAE version 3.0. Using a modified two-stage Simon design (Stage I and II), a total of 43 patients were to be included providing there were 3 of 18 patients with objective response in Stage I of the study.\nRESULTS: In Stage I of the study 20 patients (14 males, 6 females), median age 67\u00a0years (range 40\u2009-\u200982), performance status ECOG 0/1, with GC [14] or GOJ carcinoma [6] were enrolled. Of the 16 evaluable patients, 11 received the planned dose increase to 10\u00a0mg/m2 at cycle 2, 2 decreased to 6\u00a0mg/m2, and 3 continued on 8\u00a0mg/m2. There were no objective responses after 2\u00a0cycles of treatment. Twelve patients had stable disease for 1\u2009-\u20095\u00a0months and 4 had progressive disease. Median progression free survival (PFS) was 4.1\u00a0months (CI [1.6\u2009-\u20094.9]), median time to progression (TTP) was 2.9\u00a0months (CI [1.4\u2009-\u20094.2]). Grade 3/4 toxicities (worst grade all cycles) included 7 patients (35\u00a0%) with neutropenia, 4 patients (20\u00a0%) with anaemia, 2 patients (10\u00a0%) with thrombocytopenia, and 3 patients (15\u00a0%) with fatigue. This study was terminated at the end of Stage I due to a lack of the required (3/18) responders.\nCONCLUSIONS: This study of TP300 showed good drug tolerability but it failed to demonstrate sufficient efficacy as measured by radiological response.\nTRIAL REGISTRATION: EU-CTR 2009-012097-12 2009-09-03.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-016-2828-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5134240", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma", 
    "pagination": "779", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1e5f30ac5ad6fc5bbf06520f5cce0e6db250188108337483d66aca6d8fac61ed"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27724887"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-016-2828-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006376300"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-016-2828-6", 
      "https://app.dimensions.ai/details/publication/pub.1006376300"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70037_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-016-2828-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2828-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2828-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2828-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2828-6'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      21 PREDICATES      64 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-016-2828-6 schema:about N1b2abab321004de5be0026b0c0786209
2 N2eb62c3af36e45ff8cc8603dbec631bf
3 N2f02a44fc3f64ebe9e7e390bcd0efdfa
4 N3cad8c6f531247659ba30e84b11e7a7f
5 N462fc6f74ff645b08775bb4efb266b9e
6 N813c3faca3f641dc8cbf9a589d56f4f0
7 N8beb182f99314a8db0c071581571ad4a
8 N8fad018c69a64154bf626f1c08c21bc0
9 N9f597287673f4825b8ef7d8fa6bcb235
10 Na3f7015e0f814e5383860d5df389961d
11 Na8a21412fa034c8aa4dc19f7c11a486a
12 Naa5d50e80e0048f8844043d02b1559b6
13 Nba50a8a3c89d4e99a591a36af75740e4
14 Nbb3bec3fa8d24f878ea5a99230a2b8d4
15 Nd982b8c1919f44df93ed9e7e047d857e
16 Nfe3d746c84614fa5bb85a147ffbb70b2
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N6015baf1b34148c397b93e503a584149
20 schema:citation sg:pub.10.1007/s00280-009-1042-5
21 sg:pub.10.1038/sj.bjc.6601226
22 sg:pub.10.1038/sj.bjc.6690243
23 sg:pub.10.1186/1471-2407-12-536
24 https://app.dimensions.ai/details/publication/pub.1075084732
25 https://app.dimensions.ai/details/publication/pub.1075323137
26 https://doi.org/10.1002/1097-0142(197411)34:5<1576::aid-cncr2820340503>3.0.co;2-0
27 https://doi.org/10.1002/cncr.10279
28 https://doi.org/10.1016/0197-2456(89)90015-9
29 https://doi.org/10.1023/a:1008243606668
30 https://doi.org/10.1093/annonc/mdg727
31 https://doi.org/10.1093/annonc/mdh007
32 https://doi.org/10.1093/oxfordjournals.annonc.a059107
33 https://doi.org/10.1111/jphp.12065
34 https://doi.org/10.1200/jco.1999.17.1.319
35 https://doi.org/10.1200/jco.2004.01.140
36 https://doi.org/10.1215/15228517-2008-075
37 https://doi.org/10.1517/14728222.12.10.1243
38 https://doi.org/10.4143/crt.2005.37.2.79
39 schema:datePublished 2016-12
40 schema:datePublishedReg 2016-12-01
41 schema:description BACKGROUND: TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas. METHODS: Eligible patients had metastatic or locally advanced gastric or Siewert Types II or III GOJ inoperable adenocarcinoma. Patients were chemotherapy naïve unless this had been administered in the perioperative setting. TP300 was administered as a 1-h intravenous infusion every 3 weeks (a cycle) for up to 6 cycles at a starting dose of 8 mg/m2 with intra-patient escalation to 10 mg/m2 from cycle 2 in the absence of dose-limiting toxicity. Tumour responses (RECIST 1.1) were assessed every 6 weeks. Toxicity was recorded by NCI-CTCAE version 3.0. Using a modified two-stage Simon design (Stage I and II), a total of 43 patients were to be included providing there were 3 of 18 patients with objective response in Stage I of the study. RESULTS: In Stage I of the study 20 patients (14 males, 6 females), median age 67 years (range 40 - 82), performance status ECOG 0/1, with GC [14] or GOJ carcinoma [6] were enrolled. Of the 16 evaluable patients, 11 received the planned dose increase to 10 mg/m2 at cycle 2, 2 decreased to 6 mg/m2, and 3 continued on 8 mg/m2. There were no objective responses after 2 cycles of treatment. Twelve patients had stable disease for 1 - 5 months and 4 had progressive disease. Median progression free survival (PFS) was 4.1 months (CI [1.6 - 4.9]), median time to progression (TTP) was 2.9 months (CI [1.4 - 4.2]). Grade 3/4 toxicities (worst grade all cycles) included 7 patients (35 %) with neutropenia, 4 patients (20 %) with anaemia, 2 patients (10 %) with thrombocytopenia, and 3 patients (15 %) with fatigue. This study was terminated at the end of Stage I due to a lack of the required (3/18) responders. CONCLUSIONS: This study of TP300 showed good drug tolerability but it failed to demonstrate sufficient efficacy as measured by radiological response. TRIAL REGISTRATION: EU-CTR 2009-012097-12 2009-09-03.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree true
45 schema:isPartOf N2ebb224565444660ba0fd65cea83b2de
46 N551d693e74714a989847316dddf14d93
47 sg:journal.1024632
48 schema:name Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
49 schema:pagination 779
50 schema:productId N3863278f26854e40bf0a1aa9fb41f022
51 N412799f46d9c4fbea763a37bed9c3721
52 N9937ce8751f34034afc6748052d53b86
53 Nc3589d861098460d9833b2f9276615d0
54 Nc95db5203bd847b79b4719bf906982b1
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006376300
56 https://doi.org/10.1186/s12885-016-2828-6
57 schema:sdDatePublished 2019-04-11T12:37
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N28051754ff18410aaf723f07afcf3eed
60 schema:url https://link.springer.com/10.1186%2Fs12885-016-2828-6
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N1b2abab321004de5be0026b0c0786209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Esophageal Neoplasms
66 rdf:type schema:DefinedTerm
67 N28051754ff18410aaf723f07afcf3eed schema:name Springer Nature - SN SciGraph project
68 rdf:type schema:Organization
69 N28cfaec442034ef38b74ef30a906ac4c rdf:first sg:person.0744661266.43
70 rdf:rest N4adecd4e1c864ce8b81f251346a4fdc6
71 N2eb62c3af36e45ff8cc8603dbec631bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Male
73 rdf:type schema:DefinedTerm
74 N2ebb224565444660ba0fd65cea83b2de schema:volumeNumber 16
75 rdf:type schema:PublicationVolume
76 N2f02a44fc3f64ebe9e7e390bcd0efdfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Neoplasm Staging
78 rdf:type schema:DefinedTerm
79 N3863278f26854e40bf0a1aa9fb41f022 schema:name doi
80 schema:value 10.1186/s12885-016-2828-6
81 rdf:type schema:PropertyValue
82 N3a85be9d7162476eac964ba0c827a93c rdf:first sg:person.01073332434.42
83 rdf:rest N28cfaec442034ef38b74ef30a906ac4c
84 N3cad8c6f531247659ba30e84b11e7a7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Adenocarcinoma
86 rdf:type schema:DefinedTerm
87 N412799f46d9c4fbea763a37bed9c3721 schema:name readcube_id
88 schema:value 1e5f30ac5ad6fc5bbf06520f5cce0e6db250188108337483d66aca6d8fac61ed
89 rdf:type schema:PropertyValue
90 N462fc6f74ff645b08775bb4efb266b9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Treatment Outcome
92 rdf:type schema:DefinedTerm
93 N4adecd4e1c864ce8b81f251346a4fdc6 rdf:first sg:person.012750060421.97
94 rdf:rest Nef868f25d7e24ee9abb0a4f13ab9cccc
95 N551d693e74714a989847316dddf14d93 schema:issueNumber 1
96 rdf:type schema:PublicationIssue
97 N5dfb62aa85c4499d936336d5c15a1f25 rdf:first sg:person.01063747552.32
98 rdf:rest Nc84b6307cadd4bf3a521b09ba2631ebf
99 N6015baf1b34148c397b93e503a584149 rdf:first sg:person.01314243636.83
100 rdf:rest Ne2c373babdbe453db849e46779f2e289
101 N813c3faca3f641dc8cbf9a589d56f4f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Aged
103 rdf:type schema:DefinedTerm
104 N89d30b9181de47e49e94ae05b9353ef3 schema:name Chugai Pharmaceuticals Europe Ltd. Turnham Green, W4 1NN, London, UK
105 rdf:type schema:Organization
106 N8beb182f99314a8db0c071581571ad4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Middle Aged
108 rdf:type schema:DefinedTerm
109 N8fad018c69a64154bf626f1c08c21bc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Female
111 rdf:type schema:DefinedTerm
112 N92ef92f4895544e4868cf31452a47c9a rdf:first sg:person.014343021421.01
113 rdf:rest N5dfb62aa85c4499d936336d5c15a1f25
114 N9937ce8751f34034afc6748052d53b86 schema:name pubmed_id
115 schema:value 27724887
116 rdf:type schema:PropertyValue
117 N9f597287673f4825b8ef7d8fa6bcb235 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Combined Modality Therapy
119 rdf:type schema:DefinedTerm
120 Na3f7015e0f814e5383860d5df389961d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Heterocyclic Compounds, 4 or More Rings
122 rdf:type schema:DefinedTerm
123 Na8a21412fa034c8aa4dc19f7c11a486a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Stomach Neoplasms
125 rdf:type schema:DefinedTerm
126 Naa5d50e80e0048f8844043d02b1559b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Kaplan-Meier Estimate
128 rdf:type schema:DefinedTerm
129 Naf0db28e49a8442b8c68e017ce119ca4 rdf:first sg:person.013162613642.37
130 rdf:rest rdf:nil
131 Nba50a8a3c89d4e99a591a36af75740e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Dipeptides
133 rdf:type schema:DefinedTerm
134 Nbb3bec3fa8d24f878ea5a99230a2b8d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Antineoplastic Agents
136 rdf:type schema:DefinedTerm
137 Nc165a8033d0a4c52ab2afcfe2d061a3d rdf:first sg:person.0630321344.57
138 rdf:rest Naf0db28e49a8442b8c68e017ce119ca4
139 Nc3589d861098460d9833b2f9276615d0 schema:name dimensions_id
140 schema:value pub.1006376300
141 rdf:type schema:PropertyValue
142 Nc84b6307cadd4bf3a521b09ba2631ebf rdf:first sg:person.01010005124.79
143 rdf:rest Nc165a8033d0a4c52ab2afcfe2d061a3d
144 Nc95db5203bd847b79b4719bf906982b1 schema:name nlm_unique_id
145 schema:value 100967800
146 rdf:type schema:PropertyValue
147 Nd982b8c1919f44df93ed9e7e047d857e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Esophagogastric Junction
149 rdf:type schema:DefinedTerm
150 Ne2c373babdbe453db849e46779f2e289 rdf:first sg:person.0715135174.33
151 rdf:rest N3a85be9d7162476eac964ba0c827a93c
152 Nef868f25d7e24ee9abb0a4f13ab9cccc rdf:first sg:person.01304662546.41
153 rdf:rest N92ef92f4895544e4868cf31452a47c9a
154 Nfe3d746c84614fa5bb85a147ffbb70b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Humans
156 rdf:type schema:DefinedTerm
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
161 schema:name Oncology and Carcinogenesis
162 rdf:type schema:DefinedTerm
163 sg:grant.5134240 http://pending.schema.org/fundedItem sg:pub.10.1186/s12885-016-2828-6
164 rdf:type schema:MonetaryGrant
165 sg:journal.1024632 schema:issn 1471-2407
166 schema:name BMC Cancer
167 rdf:type schema:Periodical
168 sg:person.01010005124.79 schema:affiliation https://www.grid.ac/institutes/grid.418587.7
169 schema:familyName Saito
170 schema:givenName Tomohisa
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010005124.79
172 rdf:type schema:Person
173 sg:person.01063747552.32 schema:affiliation https://www.grid.ac/institutes/grid.418587.7
174 schema:familyName Inatani
175 schema:givenName Michiyasu
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063747552.32
177 rdf:type schema:Person
178 sg:person.01073332434.42 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
179 schema:familyName Anthoney
180 schema:givenName D. Alan
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073332434.42
182 rdf:type schema:Person
183 sg:person.012750060421.97 schema:affiliation https://www.grid.ac/institutes/grid.412918.7
184 schema:familyName Ford
185 schema:givenName Daniel
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012750060421.97
187 rdf:type schema:Person
188 sg:person.01304662546.41 schema:affiliation https://www.grid.ac/institutes/grid.412914.b
189 schema:familyName Eatock
190 schema:givenName Martin
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304662546.41
192 rdf:type schema:Person
193 sg:person.01314243636.83 schema:affiliation https://www.grid.ac/institutes/grid.4868.2
194 schema:familyName Propper
195 schema:givenName David
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314243636.83
197 rdf:type schema:Person
198 sg:person.013162613642.37 schema:affiliation https://www.grid.ac/institutes/grid.8756.c
199 schema:familyName Evans
200 schema:givenName T. R. Jeffry
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013162613642.37
202 rdf:type schema:Person
203 sg:person.014343021421.01 schema:affiliation https://www.grid.ac/institutes/grid.426467.5
204 schema:familyName Agarwal
205 schema:givenName Roshan
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014343021421.01
207 rdf:type schema:Person
208 sg:person.0630321344.57 schema:affiliation https://www.grid.ac/institutes/grid.418587.7
209 schema:familyName Abe
210 schema:givenName Masaichi
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630321344.57
212 rdf:type schema:Person
213 sg:person.0715135174.33 schema:affiliation N89d30b9181de47e49e94ae05b9353ef3
214 schema:familyName Jones
215 schema:givenName Keith
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715135174.33
217 rdf:type schema:Person
218 sg:person.0744661266.43 schema:affiliation https://www.grid.ac/institutes/grid.415720.5
219 schema:familyName Mansoor
220 schema:givenName Wasat
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744661266.43
222 rdf:type schema:Person
223 sg:pub.10.1007/s00280-009-1042-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031264262
224 https://doi.org/10.1007/s00280-009-1042-5
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/sj.bjc.6601226 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003666440
227 https://doi.org/10.1038/sj.bjc.6601226
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/sj.bjc.6690243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039335865
230 https://doi.org/10.1038/sj.bjc.6690243
231 rdf:type schema:CreativeWork
232 sg:pub.10.1186/1471-2407-12-536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005309595
233 https://doi.org/10.1186/1471-2407-12-536
234 rdf:type schema:CreativeWork
235 https://app.dimensions.ai/details/publication/pub.1075084732 schema:CreativeWork
236 https://app.dimensions.ai/details/publication/pub.1075323137 schema:CreativeWork
237 https://doi.org/10.1002/1097-0142(197411)34:5<1576::aid-cncr2820340503>3.0.co;2-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039330995
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1002/cncr.10279 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005653195
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1016/0197-2456(89)90015-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053744925
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1023/a:1008243606668 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056302730
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1093/annonc/mdg727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016118999
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1093/annonc/mdh007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044779901
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1093/oxfordjournals.annonc.a059107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082507231
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1111/jphp.12065 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013198532
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1200/jco.1999.17.1.319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074511243
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1200/jco.2004.01.140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016694337
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1215/15228517-2008-075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064414376
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1517/14728222.12.10.1243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046772657
260 rdf:type schema:CreativeWork
261 https://doi.org/10.4143/crt.2005.37.2.79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072255610
262 rdf:type schema:CreativeWork
263 https://www.grid.ac/institutes/grid.412914.b schema:alternateName Belfast City Hospital
264 schema:name Northern Ireland Cancer Clinical Trials Unit, Belfast City Hospital, East Podium, C Floor, BT9 7AB, Belfast, UK
265 rdf:type schema:Organization
266 https://www.grid.ac/institutes/grid.412918.7 schema:alternateName Birmingham City Hospital
267 schema:name Cancer Research Clinical Trials Team, Old Clinical Investigations Building, City Hospital, Dudley Road, B18 7QH, Birmingham, UK
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.415720.5 schema:alternateName The Christie Hospital
270 schema:name Department Medical Oncology, Christie Hospital, Wilmslow Road, Withington, M20 4BX, Manchester, UK
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.418587.7 schema:alternateName Roche (Japan)
273 schema:name Chugai Pharmaceutical Co., Ltd, Nihonbashi Muromachi 2-1-1, Chuo-ku, 103-8324, Tokyo, Japan
274 rdf:type schema:Organization
275 https://www.grid.ac/institutes/grid.426467.5 schema:alternateName St Mary's Hospital
276 schema:name West London Cancer Research Network, Coulter Suite, 1st Floor Mint Wing, St Mary’s Hospital, Praed St, W2 1 NY, London, UK
277 rdf:type schema:Organization
278 https://www.grid.ac/institutes/grid.4868.2 schema:alternateName Queen Mary University of London
279 schema:name Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Lower Ground Floor, Old Anatomy Building, Charterhouse Square, EC1M 6BQ, London, UK
280 rdf:type schema:Organization
281 https://www.grid.ac/institutes/grid.8756.c schema:alternateName University of Glasgow
282 schema:name Beatson West of Scotland Cancer Centre, University of Glasgow, G12 OYN, Glasgow, UK
283 rdf:type schema:Organization
284 https://www.grid.ac/institutes/grid.9909.9 schema:alternateName University of Leeds
285 schema:name St James Institute of Oncology, University of Leeds & Leeds Teaching Hospitals Trust, LS9 7TF, Leeds, UK
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...